Mycobacterium avium (MAC) lung disease in post-COVID-19 bronchiectasis: a need for caution as a potential risk factor for MAC infection

Mycobacterium avium (MAC) lung disease in post-COVID-19 bronchiectasis: a need for caution as a potential risk factor for MAC infection

Blog Article

Abstract Bronchiectasis due to previous tuberculosis is known to precede Mycobacterium avium (MAC) lung disease.Coronavirus disease 2019 (COVID-19) is an emerging infectious disease, and residual bronchiectasis following COVID-19 is puffy spa headband common as well as tuberculosis.However, there have been no reports documenting MAC lung disease secondary to bronchiectasis post-COVID-19 until now.We present the case of an 84-year-old patient on steroid therapy for alveolar hemorrhage who developed COVID-19, resulting in residual bronchiectasis.Despite no evidence of chronic airway infection immediately prior to the COVID-19 infection, the patient developed pulmonary MAC disease 2 years later.

This is the first report of MAC lung disease secondary to ucsb gaucho blue bronchiectasis following COVID-19.Similar cases are likely to occur in the future, necessitating caution.